Clinical Trials Browser

Hodgkin Disease, Recurrence

Triple Negative Breast Neoplasms

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Uterine Cervical Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Hodgkin Disease

Breast Neoplasms

Breast Neoplasms

Rhabdomyosarcoma

Breast Neoplasms

Uterine Cervical Neoplasms

Lung Diseases, Interstitial

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Breast Neoplasms, Recurrence

Metastatic HER2-positive Breast Cancer

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Locally Advanced Non-Small Cell Lung Cancer

Hodgkin Disease, Recurrence

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Breast Neoplasms

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Sarcoma, Desmoplastic Small Round Cell Tumor

Breast Neoplasms

Rhabdomyosarcoma, Sarcoma

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Rhabdomyosarcoma

Fludzoparib" and Anti-angiogenic

Colonic Neoplasms

Advanced Breast Cancer

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Clinical Trials

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

TroFuse-020

ASPEN-09-03

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

IMMUNOLIFE2

CAMPFIRE

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

innovaTV 301

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

ARCADIAN

FIL_A-BEGEV

TROPION-Lung12

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

LUNG-05

ESMART

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

CheckMate 816

AZALEA

COMET

BRIDGE

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

TrasTUCAN

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Evolutionary Therapy for Rhabdomyosarcoma

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

PRECIOUS

ATREZZO

ALPHABET

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

EORTC1616

VINOREAL

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma